KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Operating Leases (2019 - 2025)

Historic Operating Leases for Twist Bioscience (TWST) over the last 7 years, with Q4 2025 value amounting to $98.0 million.

  • Twist Bioscience's Operating Leases rose 1868.16% to $98.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $98.0 million, marking a year-over-year increase of 1868.16%. This contributed to the annual value of $61.8 million for FY2025, which is 1206.33% down from last year.
  • Twist Bioscience's Operating Leases amounted to $98.0 million in Q4 2025, which was up 1868.16% from $61.8 million recorded in Q3 2025.
  • Twist Bioscience's Operating Leases' 5-year high stood at $98.0 million during Q4 2025, with a 5-year trough of $22.2 million in Q1 2021.
  • Moreover, its 5-year median value for Operating Leases was $80.0 million (2022), whereas its average is $76.3 million.
  • In the last 5 years, Twist Bioscience's Operating Leases tumbled by 3499.14% in 2021 and then skyrocketed by 25812.8% in 2022.
  • Over the past 5 years, Twist Bioscience's Operating Leases (Quarter) stood at $60.3 million in 2021, then surged by 55.88% to $94.0 million in 2022, then dropped by 2.23% to $91.9 million in 2023, then dropped by 10.08% to $82.6 million in 2024, then rose by 18.68% to $98.0 million in 2025.
  • Its last three reported values are $98.0 million in Q4 2025, $61.8 million for Q3 2025, and $78.1 million during Q2 2025.